High Carbapenem Resistance in Clinical Gram-Negative Pathogens Isolated in Egypt

Microb Drug Resist. 2017 Oct;23(7):838-844. doi: 10.1089/mdr.2015.0339. Epub 2017 Feb 13.

Abstract

The emergence and spread of carbapenem-resistant gram-negative bacteria poses a serious threat to human health worldwide. Currently, little is known about the molecular mechanisms underlying carbapenem resistance and their prevalence among gram-negative bacteria in Egypt. In this study, we analyzed carbapenemase production in gram-negative bacteria isolated from hospitalized patients in Egypt in 2014. All isolates were subjected to phenotypic and genotypic susceptibility testing for carbapenem resistance. Our results indicated a high level of carbapenem-resistant gram-negative bacteria in Egypt, with 50.8% of the isolates harboring at least one carbapenem resistance gene. OXA-48-like and NDM-1 were the most prevalent carbapenemases, being detected in 49.2%, and 47.7% of carbapenemase-positive isolates, respectively, whereas Verona integron-encoded metallo-β-lactamase (VIM) was detected in only 26.2% of carbapenemase-positive isolates. This study reports for the first time carbapenemase-producing Serratia marcescens, Morganella morganii, and blaVIM-1-like-producing Pseudomonas aeruginosa in Egypt. It is also the first demonstration of the coexistence of different carbapenemases, being detected in 21.5% of carbapenemase-positive isolates. Effective antibiotic supervision, regional surveillance, and early detection of carbapenemase producers are imperative to prevent their future spread to epidemic levels.

Keywords: Egypt; Escherichia coli; Klebsiella pneumoniae; Pseudomonas aeruginosa; Serratia marcescens; carbapenemases.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Carbapenems / pharmacology
  • Egypt / epidemiology
  • Enterobacteriaceae Infections / drug therapy
  • Enterobacteriaceae Infections / epidemiology
  • Enterobacteriaceae Infections / microbiology
  • Escherichia coli / classification
  • Escherichia coli / drug effects
  • Escherichia coli / genetics*
  • Escherichia coli / isolation & purification
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / epidemiology
  • Escherichia coli Infections / microbiology
  • Gene Expression
  • Hospitals
  • Humans
  • Integrons
  • Microbial Sensitivity Tests
  • Morganella morganii / classification
  • Morganella morganii / drug effects
  • Morganella morganii / genetics*
  • Morganella morganii / isolation & purification
  • Phylogeny
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / epidemiology
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / classification
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / genetics*
  • Pseudomonas aeruginosa / isolation & purification
  • Serratia Infections / drug therapy
  • Serratia Infections / epidemiology
  • Serratia Infections / microbiology
  • Serratia marcescens / classification
  • Serratia marcescens / drug effects
  • Serratia marcescens / genetics*
  • Serratia marcescens / isolation & purification
  • beta-Lactam Resistance / genetics*
  • beta-Lactamases / genetics*
  • beta-Lactamases / metabolism

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactamases